Curian Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Curian Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-23,133	Closed	-$2.91M	–	372
2015 Q4	$2.91M	Sell	23,133 -42,321	-65%	-$5.11M	0.22%	103
2015 Q3	$6.82M	Sell	65,454 -23,850	-27%	-$3.06M	0.18%	136
2015 Q2	$11M	Sell	89,304 -1,793	-2%	-$226K	0.19%	140
2015 Q1	$10.7M	Sell	91,097 -4,504	-5%	-$540K	0.18%	141
2014 Q4	$11.4M	Sell	95,601 -9,568	-9%	-$1.08M	0.19%	123
2014 Q3	$11.8M	Buy	105,169 +24,169	+30%	+$2.3M	0.21%	117
2014 Q2	$7.67M	Sell	81,000 -24,700	-23%	-$1.73M	0.13%	180
2014 Q1	$7.47M	Sell	105,700 -60,586	-36%	-$4.8M	0.13%	181
2013 Q4	$12.4M	Buy	166,286 +38,141	+30%	+$2.66M	0.22%	108
2013 Q3	$9.72M	Buy	128,145 +44,685	+54%	+$3.56M	0.17%	128
2013 Q2	$6.68M	Buy	+83,460	New	+$6.15M	0.12%	159

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Curian Capital's VRTX Position: Q1 2016 in Review

Curian Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2016, closing a stake of 23,133 shares — an estimated $2.91M sold.

Curian Capital first reported a position in VRTX in Q2 2013 and held it in 11 quarters. The position peaked at $12.4M in Q4 2013. 502 funds tracked by Wall St. Rank hold VRTX as of Q1 2016.

Curian Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Curian Capital sold 23,133 Vertex Pharmaceuticals shares in Q1 2016, an estimated $2.91M.
Curian Capital first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Curian Capital's Vertex Pharmaceuticals position peaked at $12.4M in Q4 2013.
502 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2016.

Based on Curian Capital's 13F filing for Q1 2016.